Detailed FundamentalsSingle-page fundamentals layout — broad valuation, growth, profitability, health, competitors, top funds & analyst detail.
Price chartUnavailable
Loading price history...
52-Week Range
Trailing twelve months
$89.25$132.58
1-Month Range
Month up 12.5%
$108.62$122.85
Daily Price Range
Day up 1.6%
$117.84$122.33
Volume
vs 2M avg
2991302M avg
Profile
Identity and capital structure
SectorUnclassified
IndustryCommon Stock
Market Cap$24.9B
Short % of Float—
Employees—
Sales$5,141M
Shares Outstanding203,832,492
IPO Date—
Last Reported Qtr.—
Next Qtr. Report—
Headquarters—
Homepagewww.incy.com
Incyte Corp — Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host diseas….· via yahoo
Warnings
1 signal
Live
- No material red flags detected in fundamental screen
Scores
0–100 · higher is better except where noted · Insider Sent: directional buy ratio (excl. gifts/grants)
Value
71
Growth
89
Quality
51
Sentiment
83
Insider Sent.
0
Piotroski F
5
Altman Z
10.4
Consensus rating unavailable — no analyst coverage on file for INCY.
Price targets unavailable — no 12-month targets on file for INCY.
Valuation Engine
DCF Intrinsic Valuation Model
Run an interactive 5-year Discounted Cash Flow valuation on INCY, calculate Margin of Safety, and stress-test WACC discount hurdles.
RetrievedQuote: Live · Insiders: Live · Fundamentals/Benchmarks: Curated · Vantage Composite · 1 warnings surfacedNov 11, 2026, 6:08 PM UTC